POET Technologies Banks $400M From Single Investor as Production Scale-Up Targets 2027 – But Stock Sinks on Dilution Angst

Institutional investor MMCAP injects $400M into POET via discounted shares, but dilution and a 2x leveraged ETF amplify stock volatility. CEO plans to fund manufacturing scale-up.

A single institutional investor has handed POET Technologies a $400 million lifeline, but the market is punishing the optical chip developer for the price of that cash. Shares of the company swung wildly on Tuesday, tumbling as much as 11% to an intraday low of $12.57 before recovering to close at $13.07 — still down 8% on the day.

The capital comes from MMCAP International, which snapped up just over 19 million newly issued shares at $21 apiece, a slight premium to the prevailing market price at the time of pricing. Each share also carries a warrant to buy additional stock at $26.25, adding another layer of potential dilution. Investors are voting with their feet: the sheer weight of new paper hitting the float has overshadowed any excitement about a bulging treasury.

Volatility is being amplified by a structural factor that emerged in May — a 2x leveraged ETF tied to POET’s daily moves. That product has magnified the stock’s swings, leaving it especially vulnerable to sentiment shifts as the company transitions from development to mass production.

CEO Suresh Venkatesan is betting the $400 million war chest will fund a tenfold increase in manufacturing capacity by 2027, targeting wafer fabrication and optical engine assembly for AI-driven data centers. To lead that push, POET has hired Dr. Sandeep Kumar as chief operating officer. The Silicon Labs and Lucent Technologies veteran will oversee the ramp-up in Malaysia, where production floors are already being readied. The company’s Singapore lab has nearly tripled in size over the past year, and the global workforce has swelled to more than 115 people.

On the commercial front, POET recently inked a $50 million supply agreement with Lumilens, providing a tangible revenue path. Yet the company also suffered a blow: the loss of contracts from chip giant Marvell, which continues to weigh on sentiment. First-quarter revenue came in at just over $500,000 — a threefold improvement year-over-year but still a fraction of what the market had hoped for. The net loss for the period stood at $12.3 million, or 8 cents per share.

The balance sheet offers some comfort: debt is extremely low, and the $400 million injection should fund operations through the planned production start in 2027. Management is also exploring a relocation of the corporate headquarters to the United States, a move designed to attract American investors. For now, however, the chasm between the company’s soaring ambitions and its modest current revenue leaves the stock vulnerable to further turbulence. Kumar will have to prove he can bridge that gap — and fast.